Serradimigni A, Mathieu P, Sainsous J, Chiche G, Egré A
Arch Mal Coeur Vaiss. 1981 Mar;74(3):347-56.
120 patients with ilio-caval thrombosis were managed medically. 55 patients were given heparin (5 mg/Kg/day for 15 days), 50 patients received streptokinase (loading dose 250,000 u; maintenance dose 100,000 m/h for 48 hours) and 15 patients had urokinase (112,500 u/h for 44 hours). Thrombolytic therapy was prescribed, in the absence of contraindications, for patients below 70 year of age: other patients were treated with heparin. The results were assessed by venography performed before and after treatment: success was defined as the complete disappearance of the thrombus of disobliteration of the ilio-caval axis. The overall success rate was 32%, with 68% failures. Success was higher with streptokinase (50%) than with heparin (20%) or urokinase (13%). The site, extension ans aetiology of the thrombosis did not affect the results. On the other hand, two other factors seemed to play an important role: - the duration of thrombosis: this only affected the streptokinase group; 23 of the 25 successes were obtained in patients treated before the tenth day. The results were unaffected by the duration of the thrombosis in the heparin group; - the biological effectiveness of therapy: 7 out of the 11 successes in the heparin group had been constantly well anticoagulated; there were only 4 successes out of 38 patients in whom the biological effectiveness had been intermittent. There were 21 successes out of 32 patients treated by streptokinase with serum fibrin levels of less than 1 g. There were only 4 successes in the 18 other cases. The incidence of haemorrhage was identical in the 3 groups. Embolism was slightly commoner in the streptokinase (3) than in the heparin group (2).
120例髂股静脉血栓形成患者接受了内科治疗。55例患者给予肝素(5mg/kg/天,共15天),50例患者接受链激酶(负荷剂量250,000单位;维持剂量100,000单位/小时,共48小时),15例患者使用尿激酶(112,500单位/小时,共44小时)。对于年龄在70岁以下且无禁忌证的患者,采用溶栓治疗;其他患者则用肝素治疗。通过治疗前后的静脉造影评估结果:成功定义为血栓完全消失或髂股静脉轴再通。总体成功率为32%,失败率为68%。链激酶治疗的成功率(50%)高于肝素(20%)或尿激酶(13%)。血栓形成的部位、范围和病因不影响治疗结果。另一方面,另外两个因素似乎起重要作用: - 血栓形成的持续时间:这仅影响链激酶治疗组;25例成功患者中有23例是在发病第10天之前接受治疗的。肝素治疗组的结果不受血栓形成持续时间的影响; - 治疗的生物学有效性:肝素治疗组11例成功患者中有7例抗凝效果持续良好;在抗凝效果间歇性出现的38例患者中,仅有4例成功。链激酶治疗的32例患者中,血清纤维蛋白水平低于1g的有21例成功。其他18例中仅有4例成功。3组的出血发生率相同。链激酶治疗组的栓塞发生率(3例)略高于肝素治疗组(2例)。